Abstract
The bladder cancer (BC) is the second most common malignancy of the urinary tract and is accounted for about 165,000 deaths/year in the worldwide. The main therapies for BC include BCG immunotherapy and chemotherapy. However, the effectiveness of these therapies is limited. The BC intravesical treatment is a challenge due to low permeability of the molecules into urothelium and low reside…